30 closest matches · ranked by relevance
Bleeding · Implants · Breakthrough Bleeding
Primary: Total Number of Consecutive Bleeding-free Days in First 30 Days From Day 1 of First Treatment (TX1) — 18.5; 8.7 days
Intrauterine Devices, Copper · Metrorrhagia · Menstruation
Primary: Evaluate Changes in Bleeding Duration Among Women Initiating the Copper T380 IUD During the 90 Days Prior to Initiation Compared to Two 90 Periods After IUD Insertion…
Etonogestrel Contraceptive Implant, Bothersome Bleeding
Primary: Impact of Aygestin (and Dose of Aygestin) on the Management of Bothersome Bleeding Associated With the Etonogestrel Contraceptive Implant — 2.73; 2.77; 2.76; 2.27 units…
Contraception · Bleeding
Primary: Number of Bleeding/Spotting Days With Use of Ulipristal Acetate as Measured by Daily Bleeding Diaries — 7; 12 days — p=0.002
Menstruation Disturbances
Primary: Bleeding Days — 65.6; 46.9 days
Uterine Hemorrhage · Contraception
Primary: Cessation of Vaginal Bleeding — 37.5; 87.5 percentage of participants
Bleeding · Implants · Breakthrough Bleeding
Primary: Total Number of Days Without Bleeding or Spotting — 17.5; 16.7 days
Menorrhagia · Metrorrhagia · Medicated Intrauterine Devices
Primary: Number of Bleeding and Spotting Days — 16.8; 12.0 days
Contraception
Primary: Percentage of Participants With Ovulation Incidence, by Cycle — 0; 0; 0; 0 Percentage of Participants
Venous Thromboembolism · Menstruation
Primary: PBAC Scores — 292; 146 score on a scale
Contraceptives, Oral
Primary: Differences in Bleeding Patterns Between Study Groups. — 26.72; 31.86; 25.69; 18.84 days
Dysfunctional Uterine Bleeding
Primary: Cessation of Bleeding Within 5 Days — 48 participants
Breakthrough Bleeding
Primary: Endometrial Matrix Metalloproteinase Expression by Gel Densitometry — 1.33; 2.49 relative expression
Breakthrough Bleeding
Primary: Days With Bleeding and/or Spotting During Active Cycle 1 (Day 1-84) — 13; 13.5; 15; 15 days
Metrorrhagia
Primary: Mean Number of Bleeding or Spotting Days — 16; 28 days
Menorrhagia
Primary: Mean Days of Bleeding and Spotting, Spotting Only and Bleeding Only for the 84 Day Treatment Cycles and Last 28 Day Post-treatment Cycle — 29.2; 23.0; 9.3; 9.6 days…
Contraception Behavior
Primary: Number of Participants With Implant Continuation — 219; 225 Participants
ESI-related Bleeding
Primary: Secondary Treatment — 20; 23 Participants — p=0.37
Contraception · Bleeding
Primary: Number of Bleeding and Spotting Days — 27.5; 32; 44 DAYS — p=.03
Menorrhagia
Primary: Participants With Treatment-Emergent Adverse Events (AEs) — 218; 1; 3; 60 participants
Abortion
Primary: Number of Participants Who Use Patch After Abortion, by Study Arm — 36; 42 Participants
Menorrhagia
Primary: Number of Participants With Successful Treatment of Heavy Menstrual Bleeding — 81; 83 Participants
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Primary: Follicle-stimulating Hormone — 5.01; 5.86; 6.38 milli international units per milliliter — p=0.88
Heavy Menstrual Bleeding
Primary: Hot Flush Frequency Total Score (HFRS) Change — 9.3; 8.8; 12.7 score on a scale
Blood Loss
Primary: Volume of Intraoperative Blood Loss — 91.5; 52.2 milliliters
Premenstrual Dysphoric Disorder
Primary: Pre-Post Change in Premenstrual Symptom Severity — 1.93; 1.73; 1.64 units on a scale
Metrorrhagia
Primary: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms — 0.295; 0.012 Proportion of participants — p=< 0.0001
Metrorrhagia
Primary: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms — 0.292; 0.029 Proportion of participants — p=< 0.0001
Premenstrual Syndrome · Depression
Primary: Percent Change in Luteal Montgomery-Asberg Depression Rating Scale (MADRS) — -43.6; -38.9 percent change — p=.59
Heavy Menstrual Bleeding
Primary: Change From Baseline Menses for Participant Perceived Blood Loss — 3; 1.9 score on a scale